DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hurler syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHurler syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hurler syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alpha-L-iduronidase (IDUA) — IDUA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r},2~{r},3~{r},4~{s},6~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6I6R · 2.02 Å · ligand (1~{R},2~{R},3~{R},4~{S},6~{S})-6-azanyl-2,3,4-tris(oxidanyl)cyclohexane-1-carboxylic acid (H62). Experimental structure, not a prediction.
What the evidence adds up to
Hurler syndrome is a rare lysosomal storage disorder with a prevalence of 1 in 100 000, caused by a defective IDUA gene that codes for α-L iduronidase. Enzyme deficiency leads to accumulation of dermatan and heparan sulfate in multiple tissues, resulting in progressive deterioration and eventual death. The condition manifests with profound intellectual disability, corneal clouding, cardiac disease, and characteristic musculoskeletal abnormalities. Without treatment, patients often do not survive beyond school-aged years.
Three atypical patients have been described who presented with clinical and laboratory findings of Hurler syndrome—including characteristic facies, mental retardation, corneal clouding, dysostosis multiplex, restricted joint mobility, and hepatosplenomegaly—but without α-L-iduronidase deficiency. In these patients, α-L-iduronidase activities in leucocytes and liver tissues were within the normal range or somewhat elevated, and they excreted excessive amounts of chondroitin sulfate B and heparitin sulfate in urine.
A 2016 case report describes a 10-year-old boy diagnosed on the basis of classical clinical and radiological features, and states that early diagnosis, genetic counselling, and regular follow-up with recent modalities of treatment can decrease mortality significantly and allow the child to grow normally. A 2020 case report describes a patient with Hurler syndrome who also developed breast cancer with metastasis. A 2015 case report of a 7-year-old girl focuses on oral, dental, and radiographic findings.
What is still missing is evidence from controlled trials that any specific treatment—beyond general supportive care—reliably alters the natural history of the disease in a measurable, reproducible way. The claim that recent modalities can decrease mortality significantly is not supported by comparative data in these abstracts, and the co-occurrence of breast cancer with metastasis in one patient raises questions about long-term outcomes that remain unaddressed. No drug is mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMJ Case Reports · 2013 · 9 citations · open access
Hurler syndrome (Mucopolysaccharidosis type I)
AbstractHurler syndrome is a rare lysosomal storage disorder with a prevalence of 1 in 100 000. It is caused by a defective IDUA gene which codes for α-L iduronidase and has an autosomal recessive inheritance. Enzyme deficiency results in accumulation of dermatan and heparan sulfate in multiple tissues which leads to progressive deterioration and eventual death.
The condition manifests with profound intellectual disability, corneal clouding, cardiac disease and characteristic musculoskeletal manifestations. …
The Tohoku Journal of Experimental Medicine · 1976 · 7 citations · open access
Atypical hurler syndrome without .ALPHA.-L-iduronidase deficiency.
AbstractThree atypical patients with clinical and laboratory findings of Hurler syndrome, but without alpha-L-iduronidase deficiency, are described. Clinical features included characteristic facies, mental retardation, corneal clouding, dysostosis multiplex, restriction of joint mobility, and hepatosplenomegaly. Excessive amounts of chondroitin sulfate B and heparitin sulfate were excreted in the urine. alpha-L-Iduronidase activities in leucocytes and liver tissues were within the normal range or somewhat elevated.
Journal of Nepal Paediatric Society · 2017 · 2 citations · open access
Hurler Syndrome
AbstractWe report a case of Hurler syndrome in 10 years old boy diagnosed on the basis of classical clinical and radiological features. Early diagnosis, genetic counseling and regular follow up with recent modalities of treatment can decrease mortality significantly and the child may grow normally.J Nepal Paediatr Soc 2016;36(3):295-297
Journal of Case Reports and Images in Oncology · 2020 · 1 citations · open access
Hurler syndrome and breast cancer with metastasis: A case report
AbstractIntroduction: This case report describes a patient with Hurler syndrome, which is an inherited disease commonly diagnosed within the first few years after birth. It has a series of facial characteristics, organomegaly, developmental impairments, and skeletal deformities to aid in its diagnosis, along with mutated or low levels of a-L-iduronidase, the keystone to the disease. Interestingly, without treatment, oftentimes patients will not survive for longer than school-aged years.
HURLER SENDROMU’NUN (MUKOPOLİSAKKARİDOZ-I) ORAL BULGULARI: OLGU SUNUMU
AbstractHurler syndrome (Mucopolysaccharidosis type I) is one of the genetic disorders involving disturbances in mucopolysaccharide metabolism resulting in increased storage of acid mucopolysaccharide in various tissues. An 7-year-old girl with Hurler syndrome is described in this article, with special emphasis on the oral, dental and radiographic findings. Key Mucopolysaccharidosis type I, oral finding, dentistywords: Hurler syndrome
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
